Chronic venous disease (CVD) affects one in four adults and covers a range of conditions from enlarged varicose veins to distressing and uncomfortable open sores known as leg ulcers. Leg ulcers are notoriously difficult to manage, especially in older people with poor skin condition, and current treatments all have a downside and less than optimal outcomes.
In the United States alone, about 600,000 procedures are carried out every year to treat CVD. The market is growing by 15 per cent annually and at current medical insurer reimbursement rates is valued at about €500 million. The European Union market is of similar size and Galway-based fledgling medical technology company Venari Medical has its sights set on capturing a chunk of both with its pioneering CVD treatment that triggers the body’s natural healing response to tackle the problem.
“The goal of all CVD treatments is to close the diseased vein, allowing blood to circulate effectively in healthy veins. For patients with leg ulcers this can mean their ulcer will heal faster and is less likely to recur, significantly improving their quality of life,” explains Dr Nigel Phelan, Venari co-founder and chief medical officer.